Group 1 - The chemical pharmaceutical sector experienced a decline at the beginning of trading on September 26, with Sunflower falling over 10% [1] - Aokang saw a drop of more than 8%, while other companies such as Shutaishen, Hengrui Medicine, Yiming Medicine, and Yuandong Biology also faced declines [1]

证券代码：300204 证券简称：舒泰神 公告编号：2025-070 舒泰神（北京）生物制药股份有限公司 2025 年第二次临时股东会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东会无增加、变更、否决提案的情况，本次股东会不涉及变更前 次股东会决议。 2、本次股东会以现场投票、网络投票相结合的方式召开。 3、为尊重中小投资者利益，提高中小投资者对公司股东会决议事项的参与 度，本次股东会对中小投资者的表决进行单独计票，中小投资者是指除上市公司 董事、高级管理人员以及单独或者合计持有公司5%以上股份的股东以外的其他 股东。 一、会议召开和出席情况 1、会议通知情况 舒泰神（北京）生物制药股份有限公司（以下简称"公司"）召开 2025 年第 二次临时股东会的通知于 2025 年 09 月 10 日在证监会指定信息披露网站（巨潮 资讯网）公告。 票系统投票的具体时间为：2025 年 09 月 25 日上午 09:15 至下午 15:00 期间的任 意时间。 出席公司 2025 年第二次临时股东会的股东（或委托代理人）492 人，代表 ...

北京市朝阳区建外大街丁 12 号英皇集团中心 8、9、11 层 8/9/11/F, Emperor Group Centre, No.12D, Jianwai Avenue, Chaoyang District, Beijing, 100022, P.R.China 电话/Tel.:010-50867666 传真/Fax:010-56916450 网址/Website:www.kangdalawyers.com 北京 西安 深圳 海口 上海 广州 杭州 沈阳 南京 天津 菏泽 成都 苏州 呼和浩特 香港 武汉 郑州 长沙 厦门 重庆 合肥 宁波 济南 昆明 南昌 北京市康达律师事务所 关于舒泰神（北京）生物制药股份有限公司 2025 年第二次临时股东会的法律意见书 康达股会字【2025】第 0422 号 致：舒泰神（北京）生物制药股份有限公司 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《上市公司 股东会规则》（以下简称"《规则》"）、《深圳证券交易所上市公司股东会网 络投票实施细则》（以下简称"《实施细则》"）、《舒泰神（北京）生物制药 股份有限公司章程》（以下简称"《公司章程》"）及舒泰神（北 ...

本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 舒泰神（北京）生物制药股份有限公司（以下简称"公司"）第六届董事会第 九次会议审议通过了《关于提请召开公司2025年第二次临时股东会的议案》，本次 股东会将于2025年09月25日采用现场表决与网络投票相结合的方式召开。《关于召 开2025年第二次临时股东会的通知》已于2025年09月09日刊登于中国证监会指定的 创业板信息披露网站。现将会议有关事项提示如下： 一、召开会议的基本情况 1、股东会届次：2025年第二次临时股东会。 证券代码：300204 证券简称：舒泰神 公告编号：2025-069 舒泰神（北京）生物制药股份有限公司 关于召开 2025 年第二次临时股东会的提示性公告 2、股东会召集人：舒泰神（北京）生物制药股份有限公司董事会。 3、会议召开的合法、合规性：公司第六届董事会第九次会议审议通过了《关于 提请召开公司2025年第二次临时股东会的议案》，决定召开股东会，召集程序符合 有关法律、行政法规、部门规章、规范性文件和公司章程的规定。 4、会议召开日期和时间： （1）现场会议召开时间为：2025年 ...

Core Viewpoint - Shuyou Shen's stock price has shown significant volatility, with a year-to-date increase of 409.18%, but recent declines in the short term raise questions about future performance [1][2]. Company Overview - Shuyou Shen (Beijing) Biopharmaceutical Co., Ltd. was established on August 16, 2002, and listed on April 15, 2011. The company primarily engages in the research, production, and sales of biological products and some chemical drugs [1]. - The main revenue sources are: 59.17% from injectable mouse nerve growth factor (Sutai), 33.19% from compound polyethylene glycol electrolyte powder, and 7.63% from other products [1]. Financial Performance - For the first half of 2025, Shuyou Shen reported revenue of 126 million yuan, a year-on-year decrease of 31.14%, and a net profit attributable to shareholders of -24.64 million yuan, a decline of 619.70% [2]. - The company has distributed a total of 771 million yuan in dividends since its A-share listing, with no dividends paid in the last three years [3]. Shareholder Information - As of June 30, 2025, the number of shareholders increased by 29.20% to 31,700, with an average of 14,327 shares held per shareholder, a decrease of 22.60% [2]. - New institutional shareholders include several funds, with notable holdings such as 15.72 million shares by Xingquan Helun Mixed A and 8.81 million shares by Xingquan Commercial Model Mixed A [3]. Market Activity - On September 18, the stock price rose by 2.00% to 37.73 yuan per share, with a trading volume of 521 million yuan and a turnover rate of 3.09%. The total market capitalization reached 18.026 billion yuan [1]. - The stock has appeared on the daily trading leaderboard seven times this year, with the most recent occurrence on June 9, where it recorded a net buy of -54.65 million yuan [1].

格隆汇9月17日丨舒泰神(300204.SZ)公布，近日，公司收到香塘集团的告知函，香塘集团于2025年09月 10日、2025年09月15日通过证券交易所集中竞价交易方式合计减持141.70万股舒泰神股份，占公司有表 决权总股本的0.30%；2025年09月11日、2025年09月16日通过证券交易所大宗交易方式减持合计477.77 万股舒泰神股份，占公司有表决权总股本的1.00%。2025年09月16日减持完成后，香塘集团及其一致行 动人合计持股比例由2025年09月10日减持前6.99%下降至2025年09月16日减持后的5.69%，减持股份触 及1%整数倍（6%），香塘集团本次减持计划实施完毕。 ...

Investment Rating - The report maintains a "Recommended" investment rating for the pharmaceutical and biotechnology industry [6] Core Viewpoints - The pharmaceutical sector has outperformed the CSI 300 index, with the Shenwan Pharmaceutical Biotechnology Index rising by 2.46% from September 1 to September 14, 2025, and by 26.80% year-to-date, surpassing the CSI 300 index by 1.16 percentage points and 11.88 percentage points respectively [1][13] - The current valuation of the pharmaceutical sector stands at 31.58 times (TTM overall method, excluding negative values), with a premium of 148.92% compared to the CSI 300 index [16] - The National Medical Products Administration (NMPA) has announced measures to optimize the review and approval process for innovative drug clinical trials, aiming to complete reviews within 30 working days for eligible applications [20] - The ongoing reforms in drug review and approval systems are expected to enhance the efficiency of clinical trials and accelerate the development of innovative drugs, benefiting companies in this sector [21] Summary by Sections 1. Biweekly Market Review - The pharmaceutical sector's performance from September 1 to September 14, 2025, shows a 2.46% increase, ranking 8th among 31 Shenwan first-level industry indices [11] - Year-to-date, the pharmaceutical sector has increased by 26.80%, also ranking 8th among the indices [13] - The top ten stocks by increase include Zhendemedical (+46.67%), Haooubo (+34.22%), and Kangwei Century (+30.28%), while the top ten stocks by decrease include Shutaishen (-24.15%) and Shanghai Yizhong (-15.39%) [17][18] 2. Important Events - On September 12, 2025, the NMPA released an announcement to support innovative drug development by optimizing the clinical trial review process [20] 3. Industry Insights - The report emphasizes the acceleration of innovative drug development in China, with significant results emerging and ongoing policy optimizations expected to further support this trend [21] - The second half of 2025 is expected to see continued focus on innovative drugs, international expansion, and the clearing of procurement processes, with specific attention to insulin and orthopedic sectors [21]

证券代码：300204 证券简称：舒泰神 公告编号：2025-068 舒泰神（北京）生物制药股份有限公司 关于持股 5%以上股东减持股份触及 1%整数倍暨减持计划实施完毕的公告 公司持股 5%以上股东香塘集团有限公司保证向公司提供的信息内容真实、 准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供信息一致。 舒泰神（北京）生物制药股份有限公司（以下简称"公司"或"舒泰神"） 于 2025 年 08 月 15 日披露了《关于持股 5%以上股东减持股份的预披露公告》（公 告编号 2025-045），香塘集团有限公司（以下简称"香塘集团"）计划在本减持计 划公告之日起 15 个交易日后的 3 个月内，即 2025 年 09 月 08 日至 2025 年 12 月 07 日期间（法律法规规定的窗口期不减持），通过证券交易所以大宗交易方式 减持股份不超过 477.77 万股，占公司总股本的 1%；以集中竞价方式减持股份不 超过 477.77 万股，占公司总股本的 1%。若计划减持期间公司有送股、配股、资 本公积金转增股本等股份变动事项，则对上述股份减持数量进行相应调 ...

Group 1 - The Shanghai Municipal Medical Procurement Management Office announced a suspension of procurement qualifications for certain drugs starting from September 16, 2025, due to non-compliance with price adjustment requirements by some companies [1] - A total of 10 drugs, comprising 15 specifications, are affected by this suspension, involving 11 companies including Shuyou Shen (Beijing) Biopharmaceutical Co., Ltd. and Sichuan Baili Pharmaceutical Co., Ltd. [1]

Core Viewpoint - The Shanghai Municipal Medical Procurement Management Office announced the suspension of procurement qualifications for certain drugs due to non-compliance with price adjustment requirements, affecting multiple companies including Shutaishen and Baili Pharmaceutical [1][2]. Group 1: Impact on Shutaishen - Shutaishen's product, Compound Polyethylene Glycol (3350) Quality Vitamin C Powder, is set to be launched on October 9, 2024, as the first domestic generic, aimed at bowel cleansing before medical procedures [1]. - Shutaishen has experienced a continuous decline in revenue for three years and has reported losses for five consecutive years, totaling over 1 billion yuan [2]. - In the first half of 2025, Shutaishen reported revenue of 126 million yuan, a year-on-year decline of 31.14%, with a net profit of -24.64 million yuan [2]. Group 2: Impact on Baili Pharmaceutical - Baili Pharmaceutical's product, Oral Solution of Enalapril Maleate, is also included in the suspended procurement list [2]. - Baili Pharmaceutical reported revenue of 113 million yuan in the first half of 2025, accounting for 66% of its parent company Baili Tianheng's revenue, with a net profit of -23.48 million yuan [2]. - Baili Tianheng's revenue has been declining due to falling sales in its chemical and traditional Chinese medicine product segments, which are crucial for supporting innovative drug research and development [2]. Group 3: Other Affected Products - Other drugs affected by the procurement suspension include Vancomycin Capsules, Betamethasone Ointment, Calcium Acetate Oral Solution, and several others from various pharmaceutical companies [3].